Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Urology · Renal Angiomyolipoma

What Do Classic, Fat-Poor, and Epithelioid Renal AMLs Mean?

At a Glance

Classic renal angiomyolipoma is usually a benign kidney tumor with visible fat. Fat-poor AML has little visible fat on scans and may resemble kidney cancer, while epithelioid AML is a rare type that can behave aggressively and requires tissue examination to assess risk.

The difference between classic, fat-poor, and epithelioid renal angiomyolipoma (AML) relates to their cell makeup, how they look on imaging scans, and their potential to cause harm. Importantly, these terms do not represent completely separate categories. “Fat-poor” is a description of how the tumor appears on an imaging scan, while “classic” and “epithelioid” describe the types of cells seen under a microscope [1][2][3]. While most angiomyolipomas are benign (non-cancerous), the specific features of your tumor determine how confident doctors can be in a diagnosis and what management plan is best for you.

Classic Angiomyolipoma

A classic renal angiomyolipoma is a benign tumor made up of three distinct tissue components: mature fat cells (adipose tissue), abnormal thick-walled blood vessels, and smooth muscle cells [2][4].

Because the fat component usually shows up very clearly on imaging scans like computed tomography (CT) and magnetic resonance imaging (MRI), classic AMLs can often be diagnosed confidently without needing a biopsy [5]. Most classic AMLs are managed with active surveillance, meaning your doctor will monitor the tumor with regular scheduled imaging scans over time rather than treating it immediately [6].

When intervention is discussed, the decision is individualized. Doctors consider risk markers such as whether the tumor is larger than 4 centimeters, is growing quickly (more than 0.25 cm per year), has large abnormal blood vessels called aneurysms (weak, bulging areas in a blood vessel) over 5 millimeters, or is causing symptoms [7][8]. However, size alone does not dictate treatment [6]. Your care team will also consider your kidney function, whether you have a genetic condition, and your plans for pregnancy. When treatment is needed to prevent or treat bleeding, doctors prefer kidney-sparing options like selective arterial embolization (a procedure that blocks the tumor’s blood supply) or a partial nephrectomy (surgically removing just the tumor) [9][10].

Fat-Poor Angiomyolipoma

The term fat-poor angiomyolipoma (also called minimal-fat or fat-invisible AML) is an imaging description, meaning the tumor has very little visible fat on a CT or MRI scan [1]. A fat-poor AML is usually a classic AML that happens to have very few fat cells, but an epithelioid AML can also look “fat-poor” on scans [4][11].

This lack of visible fat makes the tumor much harder to diagnose on standard imaging [4]. On a scan, a fat-poor AML looks very similar to renal cell carcinoma (RCC), the most common type of kidney cancer [12][13]. Radiologists can sometimes use advanced imaging techniques—like observing how the tumor absorbs contrast dye or measuring chemical shifts on an MRI—to strongly suspect an AML, but no imaging test is perfect at telling it apart from cancer [14][15][16].

Because of this uncertainty, your doctor may recommend a percutaneous biopsy (using a needle to take a small tissue sample through the skin) [17]. A biopsy can help confirm a benign AML and potentially avoid unnecessary surgery, but it is not a perfect test; the needle might miss key areas (sampling error) or the results could be inconclusive [13]. If a biopsy confidently confirms a benign, non-epithelioid AML, it is managed similarly to a classic AML [5].

Epithelioid Angiomyolipoma

Epithelioid angiomyolipoma (eAML) is a rare variant identified by a pathologist. Instead of the typical three components, it is made up predominantly of epithelioid cells, meaning the cells are shaped like epithelial cells (the cells that line the surfaces of your body) [3][18].

Unlike a benign classic AML, epithelioid AML has malignant potential—meaning its behavior can vary widely, and it can sometimes act aggressively and spread [19][18].

An eAML cannot be diagnosed by an imaging scan alone [11][20]. It is identified only when a pathologist examines tissue under a microscope [3]. To support the diagnosis, the pathologist uses immunohistochemistry, a technique applying special stains to identify specific proteins. While staining can be variable, eAMLs typically test positive for melanocytic and smooth-muscle markers, and negative for epithelial markers [21][22][23].

Because of its malignant potential, localized eAML is often treated with complete surgical removal, favoring a partial nephrectomy when possible, though a radical nephrectomy (removing the whole kidney) may be considered depending on the tumor’s size, stage, and location [24]. Having an eAML does not automatically mean the tumor will spread. Pathologists look for multiple adverse features—such as mitoses (actively dividing cells) or necrosis (areas of dead tissue)—to predict how aggressive the tumor might be and to guide follow-up care [25][18]. Targeted medications called mTOR inhibitors (such as everolimus) are not routine for early eAML, but may be used in specific cases if the tumor is advanced or unresectable [26].

Tuberous Sclerosis Complex (TSC)

It is important to determine whether an AML is sporadic (occurring randomly in one location) or linked to a genetic condition like tuberous sclerosis complex (TSC). TSC-associated AMLs are often multiple or present in both kidneys, and their management may involve different surveillance strategies or systemic treatments (like mTOR inhibitors) to shrink the tumors and preserve kidney function [27][19].

When to Seek Urgent Care

Because angiomyolipomas carry a risk of bleeding, it is important to know the warning signs. Seek emergency medical care immediately if you experience sudden, severe flank or abdominal pain, fainting or marked light-headedness, unusual weakness or pallor, a rapid heartbeat, or substantial visible blood in your urine. While these symptoms do not definitively prove your AML is bleeding, they require urgent assessment by a medical professional [9].

Common questions in this guide

Are classic and fat-poor kidney angiomyolipomas separate tumors?
Usually not. “Classic” describes the typical mix of fat, abnormal blood vessels, and smooth-muscle cells, while “fat-poor” describes how little fat is visible on a CT or MRI scan. A classic AML can therefore be fat-poor, and an epithelioid AML can also appear fat-poor.
Why can a fat-poor AML look like kidney cancer?
Fat-poor AML contains too little visible fat to have the classic appearance on routine scans, so it can resemble renal cell carcinoma, the most common kidney cancer. Special CT or MRI techniques may suggest an AML, but imaging cannot always separate it from cancer. A needle biopsy through the skin may be recommended, although sampling can miss an important area or be inconclusive.
How is epithelioid renal angiomyolipoma diagnosed?
Epithelioid AML is diagnosed when a pathologist examines tumor tissue under a microscope and finds a predominance of cells that resemble cells lining body surfaces. Special stains for proteins can support the diagnosis. A scan alone cannot reliably identify this subtype.
What treatment is usually recommended for epithelioid AML?
A localized epithelioid AML is often treated with complete surgical removal, with partial nephrectomy preferred when it can be done safely. Removing the whole kidney may be considered based on tumor size, stage, and location. Medicines called mTOR inhibitors, such as everolimus, may be used in selected advanced cases or when the tumor cannot be removed with surgery.
Do all classic or fat-poor AMLs require treatment?
No. Many classic AMLs are monitored with scheduled imaging, and a fat-poor AML that biopsy confirms as benign and non-epithelioid may be managed similarly. Intervention may be considered for symptoms, rapid growth, large aneurysms, or other individual concerns, and size alone does not determine treatment.
How does tuberous sclerosis change angiomyolipoma care?
Tuberous sclerosis complex can be associated with multiple AMLs or tumors in both kidneys. Care may involve a different imaging schedule and medicines called mTOR inhibitors, which can shrink tumors and help preserve kidney function. Clinicians tailor monitoring and treatment to the number, size, and behavior of the tumors.
What symptoms of a bleeding angiomyolipoma require emergency care?
Sudden severe flank or abdominal pain, fainting or marked light-headedness, unusual weakness or pale skin, a fast heartbeat, or substantial visible blood in the urine can signal a serious problem. These symptoms do not prove bleeding, but they require immediate emergency assessment.

Related questions

How Long Should a Stable Renal Angiomyolipoma Be Monitored? What Growth Rate Is Fast for a Renal Angiomyolipoma? Can a Renal Angiomyolipoma Turn Into Kidney Cancer? Can I Exercise Safely with a Renal Angiomyolipoma? When Is Genetic Testing Recommended for TSC and Kidney AMLs?
Show more
Can Blood Thinners Raise Renal Angiomyolipoma Bleeding Risk? Is 4 cm Still the Treatment Cutoff for Renal Angiomyolipoma? Is MRI Better Than CT for Renal AML Surveillance Imaging? Small Sporadic Renal AML: How Often Should It Be Scanned? Can a Renal AML Cause Flank Pain Without Hematuria? Why Does an Angiomyolipoma Aneurysm Increase Bleeding Risk? Can a Small Renal Angiomyolipoma Rupture or Bleed? Do Multiple Bilateral AMLs Mean Tuberous Sclerosis? How Accurate Is a Biopsy for Fat-Poor AML vs Kidney Cancer? Is Ultrasound Reliable for Monitoring a Renal Angiomyolipoma? What Does Epithelioid Renal AML Mean? Can It Spread? What Happens During a Renal Mass Biopsy for Fat-Poor AML? What Happens Next If a Fat-Poor Kidney AML Looks Cancerous? What Tests Are Needed for TSC After Finding a Kidney AML?

Get notified when new evidence is published on angiomyolipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (27)
  1. 1

    [Minimal fat renalangiomyolipoma with multiple lymph nodes enlargement and postoperative refractory lymphatic fistula: a case report and literature review].

    Zhang SJ, Zhao WH, Yu LP, et al.

    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2018; (50(4)):717-721.

    PMID: 30122777
  2. 2

    A case of large renal angiomyolipoma resulted in hydronephrosis.

    Phang WM, Tan JWD, Goh EH, et al.

    The Malaysian journal of pathology 2025; (47(2)):315-318.

    PMID: 40883245
  3. 3

    Renal angiomyolipoma: Clinico-pathologic study of 17 cases with emphasis on the epithelioid histology and p53 gene abnormalities.

    Boudaouara O, Kallel R, Dhieb D, et al.

    Annals of diagnostic pathology 2020; (47()):151538 doi:10.1016/j.anndiagpath.2020.151538.

    PMID: 32574890
  4. 4

    Renal angiomyolipomas: Typical and atypical features on computed tomography and magnetic resonance imaging.

    Labra A, Schiappacasse G, Constenla D, Cristi J

    World journal of radiology 2025; (17(2)):104282 doi:10.4329/wjr.v17.i2.104282.

    PMID: 40060953
  5. 5

    The Risks of Renal Angiomyolipoma: Reviewing the Evidence.

    Seyam RM, Alkhudair WK, Kattan SA, et al.

    Journal of kidney cancer and VHL 2017; (4(4)):13-25 doi:10.15586/jkcvhl.2017.97.

    PMID: 29090118
  6. 6

    New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.

    Restrepo JCÁ, Millan DAC, Sabogal CAR, et al.

    Journal of kidney cancer and VHL 2022; (9(1)):33-41 doi:10.15586/jkcvhl.v9i1.177.

    PMID: 35096516
  7. 7

    Evolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study.

    Keles A, Iplikci A, Arikan O, et al.

    The aging male : the official journal of the International Society for the Study of the Aging Male 2024; (27(1)):2346308 doi:10.1080/13685538.2024.2346308.

    PMID: 38709235
  8. 8

    Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy.

    Bhatt JR, Richard PO, Kim NS, et al.

    European urology 2016; (70(1)):85-90 doi:10.1016/j.eururo.2016.01.048.

    PMID: 26873836
  9. 9

    Is Size All That Matters? New Predictors of Complications and Bleeding in Renal Angiomyolipoma.

    Combes A, McQueen S, Palma CA, et al.

    Research and reports in urology 2023; (15()):113-121 doi:10.2147/RRU.S400730.

    PMID: 36968628
  10. 10

    Update on the Diagnosis and Management of Renal Angiomyolipoma.

    Flum AS, Hamoui N, Said MA, et al.

    The Journal of urology 2016; (195(4 Pt 1)):834-46.

    PMID: 26612197
  11. 11

    Advancements in the diagnosis and treatment of renal epithelioid angiomyolipoma: A narrative review.

    Yang JW, Liang C, Yang L

    The Kaohsiung journal of medical sciences 2022; (38(10)):925-932 doi:10.1002/kjm2.12586.

    PMID: 36056704
  12. 12

    Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI?

    Lim RS, Flood TA, McInnes MDF, et al.

    European radiology 2018; (28(2)):542-553 doi:10.1007/s00330-017-4988-4.

    PMID: 28779401
  13. 13

    Computed Tomography and Magnetic Resonance Findings of Fat-Poor Angiomyolipomas.

    Potretzke AM, Potretzke TA, Bauman TM, et al.

    Journal of endourology 2017; (31(2)):119-128 doi:10.1089/end.2016.0219.

    PMID: 27897036
  14. 14

    Lipid-poor renal angiomyolipoma: Differentiation from clear cell renal cell carcinoma using wash-in and washout characteristics on contrast-enhanced computed tomography.

    Xie P, Yang Z, Yuan Z

    Oncology letters 2016; (11(3)):2327-2331 doi:10.3892/ol.2016.4214.

    PMID: 26998171
  15. 15

    Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma.

    Jhaveri KS, Elmi A, Hosseini-Nik H, et al.

    AJR. American journal of roentgenology 2015; (205(1)):W79-86 doi:10.2214/AJR.14.13245.

    PMID: 26102422
  16. 16

    Renal and adrenal masses containing fat at MRI: Proposed nomenclature by the society of abdominal radiology disease-focused panel on renal cell carcinoma.

    Schieda N, Davenport MS, Pedrosa I, et al.

    Journal of magnetic resonance imaging : JMRI 2019; (49(4)):917-926 doi:10.1002/jmri.26542.

    PMID: 30693607
  17. 17

    Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.

    Park BK

    AJR. American journal of roentgenology 2017; (209(4)):826-835 doi:10.2214/AJR.17.17973.

    PMID: 28726505
  18. 18

    Renal epithelioid angiomyolipoma: A multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators.

    Pecoraro A, Amparore D, Bertolo R, et al.

    Urologic oncology 2026; (44(2)):122.e11-122.e17 doi:10.1016/j.urolonc.2025.10.018.

    PMID: 41330802
  19. 19

    Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.

    Hatano T, Egawa S

    Asian journal of surgery 2020; (43(10)):967-972 doi:10.1016/j.asjsur.2019.12.008.

    PMID: 31959574
  20. 20

    [Epithelioid angiomyolipoma of the kidney: About one case and malignant features evaluation].

    Lavrut PM, Paparel P, Decaussin-Petrucci M

    Annales de pathologie 2017; (37(2)):182-187 doi:10.1016/j.annpat.2017.01.005.

    PMID: 28318774
  21. 21

    Comprehensive Insights Into Renal Perivascular Epithelioid Cell Neoplasms: From Molecular Mechanisms to Clinical Practice.

    Dong BN, Zhan H, Luan T, Wang JS

    World journal of oncology 2024; (15(3)):372-381 doi:10.14740/wjon1794.

    PMID: 38751707
  22. 22

    Epithelioid angiomyolipoma with tumor thrombus in IVC and right atrium.

    Gupta D, Vishwajeet V, Pandey H, et al.

    Autopsy & case reports 2020; (10(4)):e2020190 doi:10.4322/acr.2020.190.

    PMID: 33344317
  23. 23

    Renal epithelioid angiomyolipoma: Histopathologic review, immunohistochemical evaluation and prognostic significance.

    Park JH, Lee C, Suh JH, et al.

    Pathology international 2016; (66(10)):571-577 doi:10.1111/pin.12458.

    PMID: 27595761
  24. 24

    Clinicopathologic analysis of renal epithelioid angiomyolipoma: Consecutively excised 23 cases.

    Tsai HY, Lee KH, Ng KF, et al.

    The Kaohsiung journal of medical sciences 2019; (35(1)):33-38 doi:10.1002/kjm2.12006.

    PMID: 30844148
  25. 25

    Renal Epithelioid Angiomyolipoma: Prognostic Implications of Targeted Immunohistochemical and Molecular Markers in Conjunction with Clinicopathologic Features.

    Sangoi AR, Lobo A, Jha S, et al.

    The American journal of surgical pathology 2025; (49(8)):781-788 doi:10.1097/PAS.0000000000002411.

    PMID: 40289813
  26. 26

    Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.

    Chuang CK, Lin HCA, Tasi HY, et al.

    International urology and nephrology 2017; (49(9)):1527-1536 doi:10.1007/s11255-017-1629-4.

    PMID: 28547571
  27. 27

    Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

    Brakemeier S, Bachmann F, Budde K

    Pediatric nephrology (Berlin, Germany) 2017; (32(7)):1137-1144 doi:10.1007/s00467-016-3474-6.

    PMID: 27585680

This page is for informational purposes only and does not constitute medical advice. Your urologist and pathology team can interpret your imaging or biopsy and recommend care for your specific renal angiomyolipoma.